Brief: Calliditas Therapeutics: Regulatory Update On EMA Process For Nefecon
22/03/2022 07:06
March 22 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* PROVIDES A REGULATORY UPDATE ON EMA PROCESS FOR NEFECON
* OPINION OF COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
(CHMP)
OF EUROPEAN MEDICINES AGENCY (EMA) CAN BE EXPECTED IN Q2, 2022
Source text for Eikon: ID:nWkr2fN6K9
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations